Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872216 | 0.83 | SRD5A2 (0.43) | SRD5A2TLR9TLR7HPGDLMNA | |
| SCHEMBL2875024 | 0.78 | NR1H2 (0.36) | ALDH1A1CDK2KMT2APOLBATR | |
| SCHEMBL5221628 | 0.78 | POLB (0.35) | HPGDALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL19885983 | 0.78 | TLR9 (0.40) | SRD5A1SRD5A2NOTUMTLR9TLR7 | |
| SCHEMBL5220154 | 0.76 | KMT2A (0.39) | ALDH1A1SMN1; SMN2LMNAKMT2APOLB | |
| SCHEMBL2877718 | 0.75 | SRD5A2 (0.49) | SRD5A1SRD5A2CYP2C9TLR9TLR7 | |
| SCHEMBL2872248 | 0.73 | SRD5A2 (0.43) | SRD5A1SRD5A2HPGDLMNA | |
| SCHEMBL2875003 | 0.72 | HRH3 (0.36) | KMT2APOLB | |
| SCHEMBL3268910 | 0.71 | HPGD (0.45) | CYP2C9PTGER1TLR9TLR7TRPV3 | |
| SCHEMBL18267395 | 0.70 | CYP2C9 (0.40) | CYP2C9PTGER1TLR9TLR7TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966199-B1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-7786109-B2 | Tricyclic amide derivatives as modulators of H3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7622466-B2 | Azaindole-2-carboxamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1960401-B1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7579351-B2 | Tricyclic amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090156583-A1 | Tricyclic Amide Derivatives | NETTEKOVEN MATTHIAS | 2009-06-18 | — | — | US | disclosed |
| US-20090005379-A1 | Azaindole-2-Carboxamide Derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | disclosed |
| CN-101321761-A | Tricyclic amide derivatives for the treatment of obesity | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| CN-101312969-A | Azaindole-2-carboxamide derivatives | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | CN | disclosed |
| EP-1966199-A1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| EP-1960401-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070135416-A1 | Tricyclic amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007065820-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007057329-A1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156583-A1 | Tricyclic Amide Derivatives | HRH4, HRH3, HCAR1 | SRD5A1 1174/4885SRD5A2 1339/4885NOTUM 2474/4885 |
| US-20070135416-A1 | Tricyclic amide derivatives | HRH4, HRH3, HCAR1 | SRD5A1 1174/4885SRD5A2 1339/4885NOTUM 2474/4885 |
| US-20090005379-A1 | Azaindole-2-Carboxamide Derivatives | HRH3, HRH4, H1-5 | SRD5A1 1649/4885SRD5A2 1359/4885NOTUM 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.